Back to search

Article

Effectiveness of REGEN-COV Antibody Combination in Preventing Severe COVID-19 Outcomes

2022-02-18

Abstract excerpt

<title>Abstract</title> <p>REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has been approved as a treatment for high-risk patients infected with SARS-CoV-2 within 5 days of their diagnosis. We used the data repositories of Israel’s largest healthcare organization to determine the real-world effectiveness of REGEN-COV treatment against COVID-19 related hospitalization, severe disea...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9b9670dd-38e3-5acb-beb9-3d09a8cd44d7
DOI
10.21203/rs.3.rs-1338153/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effectiveness of REGEN-COV Antibody Combination in Preventing Severe COVID-19 OutcomesDOI 10.21203/rs.3.rs-1338153/v1
REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity
REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 OutpatientsSemantic proximity
EFFECTIVENESS OF CASIRIVIMAB-IMDEVIMAB AND SOTROVIMAB MONOCLONAL ANTIBODY TREATMENT AMONG HIGH-RISK PATIENTS WITH SARS-CoV-2 INFECTION: A REAL-WORLD EXPERIENCESemantic proximity
REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 ResultsSemantic proximity
Subcutaneous REGEN-COV Antibody Combination for Covid-19 PreventionSemantic proximity
Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant InfectionSemantic proximity
Real-World Effectiveness of Casirivimab and Imdevimab Among Patients Diagnosed With COVID-19 in the Ambulatory Setting: A Retrospective Cohort Study Using a Large Claims DatabaseSemantic proximity
RECOMBINANT HUMAN MONOCLONAL ANTIBODIES CASIRIVIMAB/IMDEVIMAB USE IN INHIBITION OF THE SARS-CoV-2 VIRUS INFECTIONSemantic proximity
Real World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 OutpatientsSemantic proximity
Emulation of a target trial from observational data to compare effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for early treatment of non-hospitalized patients with COVID-19Semantic proximity
Phase 2 dose-ranging study of the virologic efficacy and safety of the combination COVID-19 antibodies casirivimab and imdevimab in the outpatient settingSemantic proximity
Real-world Effectiveness of Casirivimab and Imdevimab in Patients With COVID-19 in the Ambulatory Setting: An Analysis of Two Large US National Claims DatabasesSemantic proximity
Select a neighboring publication to make it the new centre.